MX2022002995A - Tratamiento de hidradenitis con inhibidores de quinasa. - Google Patents
Tratamiento de hidradenitis con inhibidores de quinasa.Info
- Publication number
- MX2022002995A MX2022002995A MX2022002995A MX2022002995A MX2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A MX 2022002995 A MX2022002995 A MX 2022002995A
- Authority
- MX
- Mexico
- Prior art keywords
- hidradenitis
- treatment
- jak inhibitors
- jak
- analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para tratar hidradenitis supurativa usando compuestos y análogos que inhiben determinadas quinasas, que incluyen la quinasa Janus (JAK).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899133P | 2019-09-11 | 2019-09-11 | |
| PCT/IB2020/058333 WO2021048736A1 (en) | 2019-09-11 | 2020-09-08 | Treatment of hidradenitis with jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002995A true MX2022002995A (es) | 2022-06-02 |
Family
ID=72473596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002995A MX2022002995A (es) | 2019-09-11 | 2020-09-08 | Tratamiento de hidradenitis con inhibidores de quinasa. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12569487B2 (es) |
| EP (1) | EP4028007B1 (es) |
| JP (1) | JP2021042204A (es) |
| KR (1) | KR20220059519A (es) |
| CN (1) | CN114667148A (es) |
| AR (1) | AR119942A1 (es) |
| AU (1) | AU2020347561B2 (es) |
| BR (1) | BR112022004221A2 (es) |
| CA (1) | CA3153676A1 (es) |
| ES (1) | ES3019413T3 (es) |
| IL (1) | IL291146A (es) |
| MX (1) | MX2022002995A (es) |
| TW (1) | TWI846947B (es) |
| WO (1) | WO2021048736A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220059519A (ko) | 2019-09-11 | 2022-05-10 | 화이자 인코포레이티드 | 키나제 억제제에 의한 한선염의 치료 |
| US20230293544A1 (en) * | 2022-03-17 | 2023-09-21 | Pfizer Inc. | Methods, dosage regimens, and compositions for treating hidradenitis |
| WO2024173764A1 (en) * | 2023-02-16 | 2024-08-22 | Alumis Inc. | Methods of treating hidradenitis suppurativa |
| WO2025257327A1 (en) * | 2024-06-13 | 2025-12-18 | Almirall, S.A. | Therapeutic approaches for the management of hidradenitis suppurativa |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| GEP201606600B (en) | 2013-02-22 | 2017-01-10 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
| CN106232122A (zh) | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
| US10973913B2 (en) * | 2016-02-16 | 2021-04-13 | Washington University | JAK inhibitors and uses thereof |
| CN109071546B (zh) | 2016-02-24 | 2021-03-02 | 辉瑞大药厂 | 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物 |
| US10323036B2 (en) * | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| EP3582813A4 (en) | 2017-02-16 | 2020-12-30 | XBiotech, Inc | TREATMENT OF SUPPURATIVE HIDRADENITIS |
| WO2019090143A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| MA52655A (fr) * | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| KR20220059519A (ko) | 2019-09-11 | 2022-05-10 | 화이자 인코포레이티드 | 키나제 억제제에 의한 한선염의 치료 |
-
2020
- 2020-09-08 KR KR1020227011306A patent/KR20220059519A/ko not_active Ceased
- 2020-09-08 BR BR112022004221A patent/BR112022004221A2/pt unknown
- 2020-09-08 AU AU2020347561A patent/AU2020347561B2/en active Active
- 2020-09-08 ES ES20771628T patent/ES3019413T3/es active Active
- 2020-09-08 US US17/641,127 patent/US12569487B2/en active Active
- 2020-09-08 MX MX2022002995A patent/MX2022002995A/es unknown
- 2020-09-08 WO PCT/IB2020/058333 patent/WO2021048736A1/en not_active Ceased
- 2020-09-08 CA CA3153676A patent/CA3153676A1/en active Pending
- 2020-09-08 EP EP20771628.3A patent/EP4028007B1/en active Active
- 2020-09-08 CN CN202080078318.5A patent/CN114667148A/zh active Pending
- 2020-09-10 TW TW109131138A patent/TWI846947B/zh active
- 2020-09-10 JP JP2020151758A patent/JP2021042204A/ja active Pending
- 2020-09-11 AR ARP200102525A patent/AR119942A1/es unknown
-
2022
- 2022-03-06 IL IL291146A patent/IL291146A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021048736A1 (en) | 2021-03-18 |
| AU2020347561B2 (en) | 2026-02-26 |
| KR20220059519A (ko) | 2022-05-10 |
| TW202123940A (zh) | 2021-07-01 |
| EP4028007B1 (en) | 2025-03-26 |
| CA3153676A1 (en) | 2021-03-18 |
| IL291146A (en) | 2022-05-01 |
| ES3019413T3 (en) | 2025-05-20 |
| AU2020347561A1 (en) | 2022-04-14 |
| JP2021042204A (ja) | 2021-03-18 |
| EP4028007A1 (en) | 2022-07-20 |
| US12569487B2 (en) | 2026-03-10 |
| TWI846947B (zh) | 2024-07-01 |
| CN114667148A (zh) | 2022-06-24 |
| NZ786079A (en) | 2025-10-31 |
| US20250032492A1 (en) | 2025-01-30 |
| AR119942A1 (es) | 2022-01-19 |
| BR112022004221A2 (pt) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002995A (es) | Tratamiento de hidradenitis con inhibidores de quinasa. | |
| GEAP202315703A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2021015826A (es) | Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| MX2024004162A (es) | Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico. | |
| WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| BR112018074238A2 (pt) | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b | |
| CL2018003213A1 (es) | Inhibidores enzimáticos. | |
| MX2020003594A (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd. | |
| MX386146B (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| GEAP202316332A (en) | Cdk2 inhibitors and methods of using the same | |
| MX2017009643A (es) | Composiciones y métodos de uso de inhibidores de tirosina quinasa. | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| MX390121B (es) | Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| MX2020012826A (es) | Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k). | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| CL2015002171A1 (es) | Métodos de tratamiento de la dificiencia de hierro con pirofosfato férrico soluble. |